Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)
Launched by ORGANON AND CO · Sep 26, 2008
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
Physicians who commonly prescribed desloratadine treatment as standard care of treatment were selected enroll participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Outpatient pediatric participants, male or female, aged 6 months to 11 years
- • Diagnosis of allergic rhinitis or chronic idiopathic urticaria
- Exclusion Criteria:
- • Known hypersensitivity to desloratadine
About Organon And Co
Organon & Co. is a global healthcare company dedicated to advancing women's health and improving patient outcomes through innovative therapies and solutions. With a strong focus on addressing unmet medical needs, Organon develops and commercializes a diverse portfolio of medicines, including reproductive health, contraception, and other critical areas affecting women's health. Committed to scientific excellence and collaboration, the company engages in clinical trials to explore new treatment avenues and enhance the quality of life for patients worldwide. Through its mission-driven approach, Organon strives to empower women and healthcare providers with the tools and resources necessary for informed decision-making and effective care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials